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Abstract
Background: Islet cell transplantation can cure type 1 diabetes (T1D), but only a minority of recipients remains insulin–
independent in the following years. We tested the hypothesis that allograft rejection and recurrent autoimmunity
contribute to this progressive loss of islet allograft function.
Methodology/Principal Findings: Twenty-one T1D patients received cultured islet cell grafts prepared from multiple
donors and transplanted under anti-thymocyte globulin (ATG) induction and tacrolimus plus mycophenolate mofetil (MMF)
maintenance immunosuppression. Immunity against auto- and alloantigens was measured before and during one year after
transplantation. Cellular auto- and alloreactivity was assessed by lymphocyte stimulation tests against autoantigens and
cytotoxic T lymphocyte precursor assays, respectively. Humoral reactivity was measured by auto- and alloantibodies. Clinical
outcome parameters - including time until insulin independence, insulin independence at one year, and C-peptide levels
over one year- remained blinded until their correlation with immunological parameters. All patients showed significant
improvement of metabolic control and 13 out of 21 became insulin-independent. Multivariate analyses showed that
presence of cellular autoimmunity before and after transplantation is associated with delayed insulin-independence
(p=0.001 and p=0.01, respectively) and lower circulating C-peptide levels during the first year after transplantation
(p=0.002 and p=0.02, respectively). Seven out of eight patients without pre-existent T-cell autoreactivity became insulin-
independent, versus none of the four patients reactive to both islet autoantigens GAD and IA-2 before transplantation.
Autoantibody levels and cellular alloreactivity had no significant association with outcome.
Conclusions/Significance: In this cohort study, cellular islet-specific autoimmunity associates with clinical outcome of islet
cell transplantation under ATG-tacrolimus-MMF immunosuppression. Tailored immunotherapy targeting cellular islet
autoreactivity may be required. Monitoring cellular immune reactivity can be useful to identify factors influencing graft
survival and to assess efficacy of immunosuppression.
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Introduction
Islet cell transplantation has considerable potential as a cure for
type 1 diabetes (T1D) [1]. In 2000, a cohort of seven patients
remained insulin-independent for one year after transplantation
under a steroid-free immunosuppressive regimen [2]. Several
groups have reported similar short-term success, using different
islet isolation and immunosuppressive regimens [3–5]. The
procedure seems safe and is associated with low morbidity [6],
but long-term insulin independence is rare [7].
At present, a major challenge is to determine which factors
influence graft survival [8]. Variables studied usually relate to the
transplantation procedure (isolation method, culture, transplanta-
tion technique, quality and quantity of the graft), the engraftment
(impaired revascularization [9], apoptosis [10], b-cell exhaustion
[11], donor characteristics) and the immunosuppressive treatment
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correlated significantly with metabolic outcome at posttransplant
month 2 [13]. Other factors are also expected to influence short-
and long-term function of islet grafts, but their identification is
difficult in view of the variability in donor and recipient
characteristics in islet transplant protocols. The methods used in
our clinical study [3,13] allow to standardize donor tissue for
cellular composition and beta cell mass [3] and thus facilitate
further analysis of immune factors. They should help examine
whether signs of islet cell auto- and alloreactivity in recipients
affect successful clinical outcome independently of graft related
variables.
T1D is an autoimmune disease characterized by T cell mediated
destruction of b-cells, in which CD4+ T helper cells seem to play a
pivotal role [14,15]. It can thus be anticipated that success of b-cell
replacement not only requires suppression of allograft rejection, but
alsopreventionof a recurrentT-cell mediated autoimmune process,
as has been demonstrated in experimental models [16,17].
Autoantibody seroconversion has been considered as a sign of
recurrent autoimmunity after whole pancreas [18] and b-cell
transplantation [19–21], but this is not a consistent finding [3].
Although diabetes-associated autoantibodies are important as
diagnostic markers of preclinical T1D [22,23], there is no direct
evidence for their role in the pathogenesis of the disease [24,25].
Consequently, islet autoantibodies have proved to be of limited
value in immune monitoring of intervention or islet transplantation
[25], eventhough correlations between pre-transplant autoantibody
status and outcome have been reported [26].
In the past, we have developed reproducible methods for
quantification of both antigen-specific cellular autoreactivity and
allograft-specific cellular cytotoxicity [27–30]. The main aim of
this study was to combine these methods with established methods
for HLA- and autoantibody detection [31,32], to identify immune
markers for successful b-cell transplantation in the same cohort of
islet graft recipients that we reported on earlier and that were
transplanted in a standardized protocol [13].
Methods
Transplantation and clinical follow-up
the protocol for this trial and supporting CONSORT checklist
are available as supporting information; see CONSORT S1 and
Protocols S1. Twenty-four consecutive patients were transplanted
with one (n=10) or two (n=14) islet cell grafts with 1–6 donors per
graft (4 donors median) after signing informed consent and under
appropriate ethical approval. As we reported previously [13], two
patients were lost to follow-up in the first year, one due to CMV
infection and another due to withdrawal of consent. Before
transplantation, one of the twenty-two remaining patients presented
alloantibodies against HLA alloantigen that was expressed on the
donor cells. As pre-immunization to alloantigens is an established
predictor of poor graft survival [33], this patient was excluded from
the current analysis (Figure 1). Relevant baseline patient character-
istics are shown in Table 1. Total number of donors per patient
ranged from 2 to 10 (6 median). Graft recipients were long-term
type 1 diabetes patients without any earlier transplantation, with
plasma C-peptide ,0.09 ng/ml, large variation in blood glucose
levels (Coefficient of variation [CV] $25%), HbA1c concentra-
tion.7% and one or more chronic diabetes lesions. Exclusion
criteria were: body weight.90 kg, active smoking, pregnancy,
disturbed liver function tests, history of hepatic disease, presence of
HLA antibodies or negative EBV serostatus.
Donor organs were procured from multiple heart-beating
donors through the Eurotransplant Foundation (Leiden, The
Netherlands) and processed at the Beta Cell Bank in Brussels to
beta cell enriched fractions that were cultured for 2–20 days
(median 6 days). The grafts were characterized by their cellular
composition – in particular the number and purity of insulin-
containing beta cells [13]. They were injected into the portal vein
of the recipient as previously described [3,6,13].
Immunosuppressive induction therapy consisted of anti-thymo-
cyte globulin (ATG, Fresenius, Fresenius Hemocare, WA, USA)
with a single infusion of 9 mg/kg and subsequently with 3 mg/kg
for 6 days except when T-lymphocyte count was under 50/mm
3.
Maintenance immunosuppression consisted of tacrolimus (Pro-
graft, Fujisawa/Pharma Logistics, dose according to trough level:
8–10 ng/ml in the first three months post transplantation, 6–
8 ng/ml thereafter) and mycophenolate mofetil (MMF, Roche,
2000 mg/day).
Graft recipients were regularly followed up for 1 year regarding
plasma C-peptide levels at glycemia 120–200 mg/dl (weekly
during the first months, monthly thereafter) and HbA1c concen-
tration. The C-peptide level over one year was calculated by the
area under the curve (AUC) of available plasma C-peptide values
in the first year after transplantation.
The decision to inject a second b-cell graft was based on the C-
peptide levels and/or variation of fasting glycemia (CV glu-
cose.25%) after the first engraftment [13]. Insulin tapering was
only considered in patients with plasma C-peptide values$1.0 ng/
ml (glycemia 120–200 mg/dl), CV fasting glycemia ,25% and
mean fasting glycemia ,125 mg/dl. It was started after month 2
at a rate of minus 2IU every 3–5 days unless patients presented
hypoglycaemic episodes (,70 mg/dl). Insulin treatment was
reintroduced after two consecutive HbA1c measurements.7.0%
(HbA1c was measured bi-monthly during the first 6 months and
monthly afterwards).
Lymphocyte Stimulation Test to determine cellular
autoreactivity
All cellular reactivity tests were performed blinded from clinical
results. Blood was drawn from patients before transplantation and
on regular intervals post transplantation (standard once every two
weeks in the first months post transplant and once every two
months until one year.). Peripheral blood mononuclear cells
(PBMCs) were isolated and processed as described before [30].
Briefly, 150.000 fresh PBMCs/well were cultured in 96 well
round-bottomed plates in Iscove’s Modified Dulbecco’s Medium
(IMDM) with 2 mMol/l glutamine (Gibco, Paisley, Scotland) and
10% pooled human serum in the presence of antigen, IL-2 (35 U/
ml) or medium alone in triplicates. After 5 days
3H-thymidine (0.5
mCI per well) was added for 16 hours and
3H-thymidine
incorporation was measured. Antigens analyzed included IA-2
(10 mg/ml), GAD65 (10 mg/ml), insulin (25 mg/ml) and tetanus
toxoid (‘third party’ antigen, 1,5 LF/ml). Results were interpreted
as stimulation index (SI) compared to medium value, where an
SI.3 was considered positive. After transplantation, positivity in
case of incidental SIs between 3 and 5 was defined based on the
pattern and frequency of cellular autoreactivity over time, blinded
from clinical outcome.
Cytotoxic T lymphocyte precursor (CTLp) assay to
determine the number of alloreactive T cells
The CTLp assay has been described in detail previously [27].
Briefly, cryopreserved PBMCs from recipients from before and
different time points after transplantation were cultured in a
limiting dilution assay (40.000 to 625 cells/well, 24 wells per
concentration) with different irradiated stimulator PBMCs ex-
Islet Transplantation Immunity
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injected b-cell grafts (50.000 cells/well, 3 to 8 different stimulators
depending on the number of donors and mismatches). Cells were
cultured for seven days at 37uC in 96-well round-bottomed plates
in RPMI 1640 medium with 3 mM L-glutamine, 20 U/ml IL-2 an
10% pooled human serum. Next, Europium-labelled graft HLA-
specific target cells (5.000 cells/well, 4 to 8 different targets) were
added to the stimulator/responder combinations for 4 hours.
Wells were scored positive if the Europium release through target
cell lysis exceeded spontaneous release +3 SD. Quantification of
CTLp frequencies was performed by computer software developed
by Strijbosch et al. [34]. Cytotoxic alloreactivity in the first year
after transplantation was analyzed blinded from clinical outcome
and classified as either low or increased, based on the CTLp
frequencies against the different mismatch combinations and their
evon over time.
Autoantibodies
All available samples were tested for islet cell autoantibodies
(ICA), autoantibodies against IA-2 protein (IA-2A) and glutamate
decarboxylase (GADA), as described before [32]. Briefly, ICA
were determined by indirect immunofluorescence and end-point
titers expressed as Juvenile Diabetes Foundation (JDF) units. IA-
2A and GADA were determined by liquid phase radiobinding
assays, and expressed as percent tracer bound. Cutoff value
determination was described before [32], and amounted to $12
JDF units for ICA, $2,6% for GADA and $0,44% for IA-2A.
Figure 1. CONSORT-style flowchart of 24 consecutive islet cell transplantation recipients.
doi:10.1371/journal.pone.0002435.g001
Table 1. Recipient characteristics
Parameter Median ( IQR) N=21
Age (yr) 42 (37–49)
Gender (M/F) 13/8
Body weight (kg) 69 (65–76)
Duration of disease (yr) 26 (19–33)
Age at onset (yr) 17 (12–24)
HbA1c (%) 7.6 (6.9–8.1)
Insulin dose (IU/kg/d) 0.7 (0.5–0.9)
Mean fasting glycemia (mg/dl) 174 (145–195)
doi:10.1371/journal.pone.0002435.t001
Islet Transplantation Immunity
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ance of autoantibodies which were not detectable before
transplantation or disappearance of previously detectable autoan-
tibodies during the first year following transplantation.
Anti-HLA antibodies
Patient sera were screened for the presence of HLA class I and
class II specific antibodies by ELISA (LAT class I & II, One
Lambda, CA). When positive, the specificity of HLA Class I
antibodies was determined by complement-dependent cytotoxicity
assay against a selected panel of 52 HLA typed donors.
Statistics
Univariate analysis of time to insulin independence was
performed by Kaplan Meier analysis, using the log rank test to
assess significance. Analysis of dichotomous data was performed by
Fischer exact test and x
2 test. Quantitative differences between
groups were analyzed by unpaired t-test and non-parametric
Mann-Whitney U test as well as one-way ANOVA.
For multivariate analyses, Cox proportional hazards regression
was used to assess time to insulin independence, binary logistic
regression to assess insulin independence at one year, and multiple
linear regression to determine differences in total C-peptide levels.
Multivariate analysis was performed in a stepwise fashion with the
p-value for entry into or removal from the analysis set at 0.20, to
allow for inclusion of variables tending towards significance in this
analysis of a relatively limited number of patients. Analyses were
performed using GraphPad Prism (version 4.0) and SPSS (version
14.0) software. P,0.05 was considered significant.
Results
Transplants and metabolic outcome
For the 21 patients studied in the current analysis, median total
b-cell mass injected was 3.9610
6 (Interquartile range [IQR]
2.9610
6 –5.0610
6) cells/kg body weight. Median b-cell mass per
transplant was 2.4610
6 (IQR 1.7610
6–3.1610
6) million cells/kg
body weight. (Transplant related parameters per patient are
available in Table S1.)
All patients showed significant improvement of metabolic
control. Out of the 21 patients examined, 20 (95%) showed b-
cell function (defined as plasma C-peptide$0.5 ng/ml) at any time
point in the first year after transplantation. Thirteen patients (62%)
achieved insulin independence. Three of these patients resumed
insulin therapy within one year after first transplantation [13].
Serology
Allo- and autoantibody data were available from all patients. Of
22 patients transplanted under the current protocol, one patient
was excluded from the current analysis because of pre-sensitization
with graft-specific HLA antibodies (see Methods section). No HLA
antibodies were observed in any of the other patients during the
course of this study.
Six out of 21 patients were positive for at least two islet
autoantibodies (ICA, GADA and IA-2A) before transplantation.
Ten patients were positive for a single autoantibody. One of the three
patients who developed new autoantibodies after transplantation
reached insulin independence, and two other patients who lost an
autoantibody reactivity both became insulin-independent. (Detailed
and individualimmune-related parameters are available in Table S1.)
Cellular reactivity
Complete data on cellular autoreactivity could be obtained from
18 out of 21 patients. Of one patient, no pre-transplantation
assessment of autoreactivity was performed for logistic reasons. In
two other cases, data on reactivity to IA2 was lacking due to
temporary unavailability of the recombinant IA2 antigen. Cellular
islet autoreactivity against GAD and/or IA-2 was detected in 10
patients (56%) before transplantation, four of them being reactive
to both autoantigens GAD and IA-2, three against GAD and three
against IA-2 only. Cellular reactivity to whole insulin protein
remained low in all patients both before and after transplantation;
therefore the response to whole insulin was excluded from the
analysis. Four out of ten patients retained cellular autoreactivity
after transplantation. Among the eight patients without detectable
cellular autoreactivity before transplantation, five developed it post
transplantation. Incidental moderate cellular autoreactivity
(3,SI,5) was detected in eight patients after transplantation;
five of these cases were interpreted as negative on basis of the
pattern in time, while three cases were judged positive in view of
their repeatedly increased cellular autoreactivity.
Alloreactive CTL precursor analysis determining donor HLA-
specific cellular cytotoxicity was performed in 20 out of 21
patients. The total number of donors per patient ranged from 2 to
10 (mean of 6), representing 9 to 29 (mean 18) HLA class I
mismatches per patient. Using extensive mismatch combinations
and large HLA panels, on average 78% of mismatches could be
evaluated per patient. By this analysis of alloreactivity, for 97% of
the grafts at least part of the HLA mismatches with the recipient
were covered. For 60% all of the grafts’ mismatches were covered.
Nine patients (45%) developed islet donor-specific alloreactive
cytotoxicity over one year, as indicated by the CTLp assay.
Association of immunological parameters with clinical
outcome
To identify possible predictors for transplant outcome, the
immunological parameters were analyzed with respect to three
clinically relevant endpoints: time to insulin-independence, insulin-
independence at one year, and C-peptide level over one year. The
immune parameters included immune suppressive therapy (Tacro-
limus trough levels, ATG and MMF dosage), pre-transplant cellular
autoreactivity, post-transplant cellular autoreactivity, post-transplant
donor HLA-specific cellular cytotoxicity, presence of pre-transplant
autoantibodies, post-transplant autoantibody seroconversion. Injec-
tion of sufficient b-cell mass (proposed earlier as $2.0610
6 b-cells per
kg body weight per injection [13]) was also analyzed.
Pre-transplant cellular autoreactivity was associated with
delayed achievement of insulin-independence (overall x
2=6.91,
p=0.03). The extent of pre-transplant cellular autoreactivity was
of additional influence, as patients reactive to both GAD and IA-2
never reached insulin-independence (log rank: x
2=6.49, p=0.01
vs. non-autoreactive patients, Figure 2A), whereas patients reactive
to a single islet autoantigen did so in four out of six cases,
(x
2=3.74, p=0.05 for time to insulin independence when
compared to double-positive patients). No such influence was
observed regarding the presence of pre-transplant autoantibody
production (Figure 2B). Tacrolimus trough level and insufficient
injected b-cell mass was also associated with delayed insulin-
independence (p=0.04 and p=0.02, respectively, Table 2). In
multivariate analysis, both pre- and post transplant cellular
autoreactivity were significantly associated with delayed insulin
independence (p=0.001, Relative Risk (RR) 0.133 [0.039–0.453])
and p=0.01, RR 0.224 [0.147–0.892]), respectively). None of the
four patients reactive against both IA-2 and GAD insulin became
independent, whereas two out of six ‘single’ cellular autoreactive
patients (33%) and six out of eight non-autoreactive patients (75%)
were insulin independent at one year (Fischer exact p=0.06).
(Quantitative pre-transplant Stimulation Indices against GAD and
Islet Transplantation Immunity
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are shown in Figure S1.)
C-Peptide level over one year was strongly associated with
cellular autoreactivity (p=0.004, Table 2), with similar baseline
characteristics and injected b-cell mass for the three groups.
Tacrolimus trough level (p=0.04) and graft size (p=0.003) also
influenced C-peptide level univariately. In multivariate analysis,
both pre-transplant (p=0.002, beta 226.73 [241.76 to 211.70])
and post-transplant cellular reactivity (p=0.02, beta 221.01
[237.65 to 24.42]), as well as graft size (p=0.03, beta 27.46
[23.64 to 51.22]) and ATG dosage (p=0.04, beta 23.95 [27.70
to 20.21]) were significantly associated with C-peptide level over
the first year (Table 2).
Neither MMF dosage nor pre-transplant autoantibody status or
post transplant seroconversion affected time to insulin indepen-
dence, insulin-independence at one year or C-peptide level over
one year (Table 1). Similarly, cellular cytotoxicity against the
HLA-allodeterminants of the islet donors did not correlate with
any of these three clinical endpoints.
Influence of cellular autoreactivity over time
The combined influence of pre-and post-transplant cellular
autoimmunity on graft function was assessed by separating the
patients into four groups: cellular autoreactivity against one or
more autoantigens before and after last transplantation (+/
+),before transplantation only (+/2), development of cellular
autoreactivity after last transplantation (2/+), and no cellular
autoreactivity at any time point (2/2). Time to insulin-
independence was associated with the cellular autoreactivity status
before and after islet transplantation (overall x
2=8.69, p=0.03 by
log rank test, x
2=5.93 and p=0.01 for trend). Insulin indepen-
dence was reached in 0 out of 4 patients in the +/+ group, 4/6 in
the +/2 group, 4/5 in the 2/+ group and 3/3 in the 2/2 group.
Injected b-cell mass was similar between the groups. C-peptide
level over the first year differed between the four groups (Figure 3,
R
2=0.55, p=0.009). The linear trend for all four groups was
highly significant (R
2=0.48, p=0.002). Differences between 2/2
and +/+ and between 2/+ and +/+ remained significant after
Bonferroni adjustment. Plasma C-peptide level over 52 weeks was
mostly affected by pre-transplant autoreactivity (R
2=0.39,
p=0.006 by unpaired t-test). Even in the first six weeks (before
any second implantation) this pattern was observed (R
2=0.36,
p=0.008 comparing C-peptide AUC in week 0–6).
Influence of pre-transplant autoreactivity is confined to
patients with low injected b-cell mass
Pre-existent cellular autoreactivity was further studied in relation
with injected b-cell mass that was previously shown to be indicative
for clinical transplant success [13]. The influence of pre-existent
cellular autoreactivity on insulin-independence was confined to the
subgroup of patients receiving amounts of b-cells lower than the
median (Fischer exact p=0.008, Figure 4). This effect lasted during
the entire follow-up. Within the patients receiving more b-cell mass
than the median, no significant influence of cellular autoreactivity
was seen. Additionally, patients with pre-existent islet autoimmunity
reached insulin independence less frequently when they had
received less than the median of b-cell mass compared to those
receiving more beta-cells (Fischer exact p=0.048), although this
difference did not persist at one year post transplant.
Discussion
The aim of this study was to identify immunological correlates
for islet transplant survival. Where we and others have described
markers of allo-and autoimmunity after islet cell transplantation
[3,18–21,28,33,35,36], our present results have possible implica-
tions for the selection and treatment of type 1 diabetic candidate
islet recipients before transplantation. Despite the limited number
of patients studied that can be studied in clinical islet transplant
trials, significant associations of clinical outcome with immuno-
logical parameters were derived from blind analysis of data in a
group of 21 islet cell recipients. When interpreting results, some
caveats need to be kept in mind. We report an exploratory study
using assays for cellular autoreactivity that have proved difficult to
perform and shown variability between institutions in the past
[37]. However, a structured approach validating our techniques
has been implemented by the T Cell Workshop of the
Immunology of Diabetes Society founded and directed by our
institute, that provided considerable experience and reproducibil-
ity [28–30,37,38]. Second, the limited number of patients inherent
to clinical islet transplantation trials combined with a large
number of immune variables studied enforced us to apply stepwise
Figure 2. Kaplan-Meier curves showing cumulative insulin independence after b-cell transplantation, stratified for A) pre-
transplant cellular autoimmunity and B) pre-transplant presence of autoantibodies. Continuous lines represent patients without
reactivity to autoantigens, striped lines patients with reactivity to a single antigen, and dotted lines patients with reactivity to two antigens (or three
in the case of autoantibodies).
doi:10.1371/journal.pone.0002435.g002
Islet Transplantation Immunity
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PLoS ONE | www.plosone.org 6 June 2008 | Volume 3 | Issue 6 | e2435multivariate analysis to assess the independence of new predictors.
This may be subject to debate because of the increased possibility
of reporting chance findings. However, while full multivariate
analysis may be preferable, the current analysis optimizes study
power and allows for detection of valuable markers which
otherwise may not have been identified in this exploratory study.
In this patient group receiving grafts with standardized cellular
composition, the injected b-cell mass was shown to be an
Figure 3. A) C-peptide levels stratified for cellular autoimmune status before and after transplantation. Total C-peptide levels over one year for
patients that are not autoreactive pre- nor post-transplant (2/2, n=3) only pre- (+/2, n=6) or only post-transplant (2/+, n=5), and both pre- and
post transplant (+/+, n=4). Areas under the curve differ significantly between groups (p=0.009, one-way ANOVA). Horizontal lines represent average
C-peptide level per group. B) average basal C-peptide levels (black lines)6SD (grey areas) over time for the four different groups. Differences between
2/2 and +/+ and between 2/+ and +/+ remain significant after Bonferroni correction. Pre-transplant autoreactivity significantly reduces total C-
peptide production (p=0.006, unpaired t-test).
doi:10.1371/journal.pone.0002435.g003
Figure 4. Influence of pre-transplant T cell autoreactivity stratified for total injected b-cell mass. Shown are pre-transplant T cell
autoreactivity and achievement of insulin independence for patients receiving more or less than the median total injected b-cell mass (the single
patient receiving the median b-cell mass is excluded). Groups are compared by Fischer exact test.
doi:10.1371/journal.pone.0002435.g004
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PLoS ONE | www.plosone.org 7 June 2008 | Volume 3 | Issue 6 | e2435important variable for clinical outcome at month 2 after
implantation [13]. We now demonstrate that cellular autoimmune
reactivity before transplantation is another variable that is
associated with achievement of insulin independence, as well as
AUC of C-peptide level over 52 weeks. Obviously, these results
will need further confirmation in larger patient cohorts with longer
follow-up. Furthermore, non-immunological factors could influ-
ence transplant survival as well and need to be assessed in future
studies.
Outcome is significantly worse in patients who showed cellular
autoreactivity prior to transplantation. This finding is unexpected,
since diabetes-associated islet autoantigens are thought to be lost in
these long-term type 1 diabetes patients prior to transplantation
[39]. These pre-existent autoreactive T cells may cause rapid
initial destruction of beta cells as is suggested by the increased need
for a second infusion (8/10 vs. 2/8 in non-autoreactive patients).
Interestingly, pre-existing GAD-specific autoreactivity in the
peripheral blood samples disappeared after transplantation in all
patients, whereas IA-2-specific autoreactivity frequently persisted.
GAD is also expressed by other tissues and therefore continuously
present as an autoantigen in the body. This notion implies that
immunological memory of autoreactivity is exerted differentially
between autoantigens and may therefore be affected differently by
immunosuppression. No cellular autoreactivity was observed to
whole insulin protein during follow-up, while insulin is considered
one of the major autoantigens in T1D. This lack of responsiveness
may result from many years of therapy with exogenous insulin, or
insufficient antigen processing and presentation. Indeed, we did
observe occasional reactivity when a specific insulin epitope (e.g.
B9-23) was tested . However, insulin epitope data were only
available for a fraction of our study population.
Eighty-eight percent of recipients lacking pre-transplant cellular
autoreactivity became insulin independent after transplantation,
with 75% remaining off insulin therapy at one year. These short-
term results are in the same range as those achieved in whole
organ pancreas transplantation [40]. Plasma C-Peptide level
(calculated by AUC over one year) gives a complete overview of
graft function, incorporating both peak and duration of C-peptide
production. C-peptide level also showed significant association
with cellular autoreactivity. Still, although none of the patients
with positivity to both GAD and IA2 before transplantation
became insulin independent, some showed considerable C-peptide
level (Table S1). To assess the influence of a possible second
transplant, the C-peptide level before any second transplant (AUC
from 0 to 6 weeks) was calculated, showing similar results.
Cellular reactivity to autoantigens after islet cell transplantation
did not correlate with graft function in univariate analysis.
However, in combination with pre-transplant autoreactivity,
post-transplant autoreactive status becomes informative, as
underscored by its significance in multivariate analysis. However,
recurrence of autoimmunity that was undetectable prior to
transplantation could represent a different process than pre-
existing autoreactivity and it is conceivable that the role of
recurrent autoimmunity may become more apparent after longer
follow-up.
The presence of autoreactive CD8
+ T-cells in islet graft
recipients losing graft function supports a particular role for
recurrent autoimmunity after islet transplantation [41]. Some
patients became insulin-independent in spite of developing islet
autoreactivity after transplantation, indicating that additional
mechanisms may be able to rescue graft function. In experimental
models, recurrent autoimmunity after islet transplantation has
been abrogated successfully [16,17], but such success has not yet
been reported in humans.
In pancreas transplantation, recurrent autoimmunity after
transplantation has been reported [18–20,42,43], but was mainly
limited to the presence of autoantibodies, that in one study have
shown impact on pancreas transplantation survival rates [44]. In
the whole pancreas transplantation program in our institute
(.90% one-year graft survival), we observed only very limited
post-transplant cellular autoreactivity. However, pre-transplant
cellular autoimmunity was not studied in these patients. Differ-
ences with our results in islet transplantation include the protective
or regenerative capacity of the non-islet pancreatic tissue,
vascularization and the smaller islet cell mass in injected islets
than in whole pancreas transplants.
Changes in islet autoantibody status did not qualify as an
independent surrogate marker for b-cell survival in this cohort.
This is in accordance with several studies describing a lack of their
association with clinical remission or therapeutic intervention [25],
but discord with earlier claims in islet or pancreas transplantation
[18–20,45]. It is conceivable that seroconversion may be a
surrogate marker for (loss of) b-cell function in some cases, but it
does not appear to reflect the primary autoimmune process
influencing transplant success. If larger series would indicate that
islet autoantibodies are associated to loss of islet graft function, our
data suggest that this is secondary to T-cell autoreactivity.
Occurrence of, or pre-sensitization with, graft-specific alloanti-
bodies is a known risk factor for transplant failure [33] but was
exceptional in our cohort. This is an important consideration in
view of the fact that these T1D patients, despite islet cell
transplantation, may need a kidney transplantation for diabetic
nephropathy in a later stage.
Perhaps surprisingly, T-cell cytotoxicity to alloantigens on the
islet grafts was not independently associated with clinical outcome.
Yet, alloreactivity against islets served as most frequent correlate
with graft failure in islet-after-kidney transplantation, as we
reported earlier [28]. Differences between islet transplantation
alone versus islet-after-kidney transplantation include precondi-
tioning of the patients with immune suppression, the type of
immune suppression (tacrolimus and MMF vs. prednisolone,
cyclosporine and azathioprine, respectively) and a history of
successful implantation of a kidney allograft years before.
Development of alloreactive CTLs did not lead to production of
graft–specific HLA antibodies in our protocol.
Explanations for the lack of correlation between alloreactivity
and islet allograft function may further relate to the notion that the
CTLp assays employed were not designed to distinguish between
high and low avidity of the T-cell receptor, where elevated
frequencies of low-avidity CTLs need not be detrimental. The
presence of effective immunosuppressive therapy may be of
additional influence in this context. Indeed, our preliminary
experiments indicate that addition of tacrolimus in the CTLp
assay suppressed allo-CTLp frequencies in a successfully trans-
planted patient, whereas allo-CTLp frequencies in a case of graft
failure remained elevated. Second, the influence of alloimmunity
may be secondary to a preimmunized autoimmune status. In this
scenario, alloreactivity may be precipitated by an initial autoim-
mune attack to the islet allograft, leading to so-called determinant
spreading that includes alloantigens [46]. Finally, the current
immunosuppressive regimen that is largely based on prevention of
allograft rejection may cope sufficiently with de novo T-cell
alloreactivity, but may prove inadequate to intervene in (pre-
existent) islet autoreactivity. The latter interpretation is supported
by earlier findings that immunosuppressive therapy (e.g., prednis-
olone, cyclosporin A, azathioprine) had at most temporary effects
on preservation of b-cell function at clinical manifestation of type 1
diabetes [47–49].
Islet Transplantation Immunity
PLoS ONE | www.plosone.org 8 June 2008 | Volume 3 | Issue 6 | e2435In conclusion, our results indicate that cellular autoimmunity
may influence survival of islet cell allografts in type 1 diabetic
recipients. The amount of autoreactivity (to one or two antigens)
has additional influence, implying a role in patient selection.
Obviously, longer follow-up and enlargement of patient cohorts
will be warranted to confirm these findings. Yet, the combination
of sufficiently large b-cell mass and a non-autoreactive recipient
currently appears the most desirable condition to perform
successful b-cell transplantation. As suggested earlier [8], longitu-
dinal analysis of auto- and alloreactivity may be a useful tool to
identify immune factors influencing graft survival and to assess
efficacy of immunosuppression. We propose that tailoring
immunosuppressive treatment of islet autoreactivity, as well as
adjusting graft size for individual patients, can improve clinical
outcome after islet cell transplantation.
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